REACH a Better Solution: in vitro Skin Sensitization Assays as Animal Testing Alternatives

REACH a Better Solution: in vitro Skin Sensitization Assays as Animal Testing Alternatives

Skin sensitization testing is a major gap for many companies addressing the 2018 REACH substance registration deadline. Join us for a Q&A session with our Covance experts as we review REACH requirements and focus on a better solution for skin sensitization studies: in vitro assays as new alternatives to animal testing.

Q: What do REACH regulations hope to achieve?

A: The European Regulation on Registration, Evaluation, Authorization and Restriction of Chemicals (REACH) places responsibility on companies to assess and manage risks posed by chemicals. They also have to provide appropriate safety information to users. The first purpose is to ensure protection of human health and the environment. Next, the regulation promotes using alternatives to animal test methods. Third, it seeks free circulation of substances to the market, with enhanced competitiveness and innovation. Continue reading

Keeping Skills Sharp For CRAs

The drug industry is evolving and clinical trials are becoming more complex. How do CRAs in a large global company keep their skills up to date? Recognizing that large group meetings are costly and virtual training feels impersonal, Covance decided to address this challenge with an innovative model called CLIK: Country Leadership Imparting Knowledge.Covance CRA Careers

With selected leaders identified from each of the 70+ countries that Covance serves, the CLIK program brings CRAs face-to-face to share their experiences, gain new knowledge and then serve as training representatives for peers in their own regional teams. Continue reading

Understanding Regulatory and Market Access Considerations With Drug Abuse Potential

Each assessment for abuse liability is as unique as the molecule in question, reiterating Regulatory And Market Access Considerations With Drug Abuse Potentialthe importance of early awareness, understanding the current regulatory landscape, and being able to plan your development and post-marketing accordingly.

In our previous blog post, we focused on the value of early drug abuse potential testing. In this blog, we’ll delve into important regulatory and market access considerations for abuse liability testing that can help drug developers maximize the potential of their molecule.

Continue reading

Getting Investigators Onboard: Lab Preferences Make a Difference in Trial Participation

Clinical trials are becoming increasingly complex and competitive, so attracting the best investigator sites to participate in a trial is a crucial step in meeting patient enrollment targets.

Delaying approval by even one day can cost hundreds of thousands of dollars or more, Covance Labs Clinical Trial Participationdepending on the drug. This means that timely trial implementation, including patient enrollment, may add significant value.

Meeting patient enrollment milestones in cooperation with investigators has traditionally been viewed as the responsibility of the contract research organization (CRO). Now, important new data show that a sponsor’s choice of a central lab impacts the willingness of investigators to work with a sponsor on clinical trials. Continue reading

Important Early Considerations For Assessing Drug Abuse Liability

covance blog drug abuse

Assessment of abuse potential of compounds in development is one of the most complex regulatory requirements and constitutes a critical exercise for sponsors and regulators. The strategy for the assessment of abuse potential cannot be customized and requires individual evaluation of the compound, its target indication and the entirety of the nonclinical and clinical safety database. In July 2016, the United States Congress passed the Comprehensive Addiction and Recovery Act (CARA) bill to address prescription opioid abuse and overdoses that have killed more than 165,000 people between 1999 and 20141.

Given this increased spotlight and focus on preventing opioid abuse and deaths in the US and abroad, it has become more critical than ever to better understand the abuse liability potential of a drug as early as possible in the development process. As part of the overall assessment of drug safety for a New Drug Application (NDA) in the United States or a Market Authorization Application (MAA) outside the United States, drug abuse potential testing is required – regardless of indication – on any drug that is active in the brain. This encompasses all properties of the drug (e.g., chemical, pharmacological, pharmacokinetic, clinical safety, etc.).

In the first of a two-part blog, we share important early considerations for abuse liability testing to help drug developers test the abuse potential of their molecule and better understand their path to viability in this changing landscape.

Continue reading

Fierce Innovation Awards Recognize Xcellerate® Trial Design As Best Data Analytics/Business Intelligence Technology

Covance is proud to announce that Xcellerate® Trial Design has been selected as the Fierce Innovation Awards Recognize Xcellerate® Trial Design winner of the Fierce Innovation Awards: Life Sciences Edition in the Data Analytics/Business Intelligence category. The Fierce Innovation Awards: Life Sciences Edition recognizes outstanding innovations that are driving improvements and transforming the life sciences industry. Xcellerate Trial Design was recognized for its innovative approach to improving site selection, forecasting resource demand and optimizing of clinical trial design. Continue reading

Computerworld Names Dimitris Agrafiotis of Covance a 2017 Premier 100 Technology Leader

Agrafiotis’ Leadership in Bringing Xcellerate® Informatics to Market Demonstrates How Software Can Improve Health and Improve Lives

IDG’s Computerworld recently recognized Dimitris Agrafiotis, PhD, chief data officer and Computerworld Dimitris Agrafiotis head of technology products for Covance Drug Development, as a 2017 Premier 100 Technology Leaders honoree. This year’s Premier 100 spotlights 100 leaders from both the technology and business sides of companies for their exceptional technology leadership and innovative approaches to business challenges. Covance is the drug development business of LabCorp.

“The Premier 100 awards program highlights the exceptional work of an elite group of IT executives who are leading their organizations through times of unprecedented change. They are using technology to drive high-stakes business projects and create dynamic growth in their organizations,” said Scot Finnie, editor in chief of Computerworld.

“These 100 men and women are not only strategic business thinkers, but also team leaders who recognize the importance of recruiting and retaining the brightest talent to enable digital transformation and harness the opportunities of cloud, big data, mobile and social. We’re pleased to recognize their leadership and honor their achievements.” Continue reading

Strategic Alliance with Global Specimen Solutions: Introducing Covance SpecimINSIGHT™

The complexity of clinical trials continues to rise. New biomarkers for safety and efficacy continue to emerge, and new types of information – such as genomic profiles – have become critical to submissions for drug approval. Against this dynamic backdrop the Global Specimen Solutions Logocentral challenge facing trial sponsors remains the same: the need to bring together diverse data sets, draw meaningful insights from them and act quickly to maximize return on investment.

Covance and Global Specimen Solutions, Inc. (GSS) have announced a five-year strategic alliance that gives Covance clients access to a comprehensive and integrated solution that includes GlobalCODE®, snapTRACKTM and GSS wraparound services. This will enable near real-time data cleaning across clinical trial data sources which allow interventions to be made during the clinical trial, impacting overall trial execution and data validity. This also allows cross-protocol, cross-program analytics which provide context for data results, assuring robust clinical trial design and operational excellence. Continue reading

TQT Waivers: One Year Later

Overcoming Design Challenges

ICH E14 REGULATORY GUIDANCE 2005 AND 2015

It has been one year since the International Conference on Harmonisation (ICH) rp_Covance-Labs-Safety-Pills-300x200.jpgupdated its 2005 cardiac safety guidelines. The 2015 update allows for specific QT interval analysis based upon concentration effect modeling up to supratherapeutic during Phase I as a reasonable substitute for a Thorough-QT (TQT) dedicated trial.  These Phase I data along with preclinical results are submitted to the FDA prior to Phase III as a waiver request from a separate TQT study. This is good news! A dedicated TQT study involving time-wise comparisons of baseline corrected data is an expensive and lengthy endeavor. It typically takes place after proof of concept but before Phase III. Collection of QT information during an existing Phase I study costs substantially less and can provide go/no-go decisions much earlier. Continue reading

Risk-Based Monitoring – Driving the Evolution of the Clinical Research Associate Role

Over the last 10 years, clinical trials have changed substantially in response to increasing globalization and study complexity, along with new technological capabilities and industry guidelines[1],7. With these noticeable transformations, sponsors are increasingly revisiting their monitoring methods to uncover new efficiencies and develop more robust risk management processes that can enhance ongoing patient safety and data quality.

At the forefront of this movement is risk-based monitoring (RBM) – a broad term for a variety of clinical monitoring methods that combine people, process and technology, enabling project teams and Clinical Research Associates (CRAs) to focus on the most important risks in clinical trials.

Clinical Research Associate Covance CRA Careers

Continue reading